What Is PMOS? The Condition That Looks Like PCOS But Behaves Differently

Why the naming matters

For decades, PCOS has been defined by three criteria: irregular periods, clinical or biochemical signs of androgen excess (acne, hair loss, elevated testosterone), and polycystic ovaries on ultrasound. Doctors have debated which two of three are necessary for diagnosis. But the focus on the word "ovary" has done women a disservice: it places the spotlight on reproductive symptoms and ovarian appearance, when the actual disease driver is sitting metabolic — in your cells' ability (or inability) to respond to insulin.

PMOS reframes the condition as primarily metabolic, with ovarian consequences. This matters because a woman with regular periods and no visible cysts but severe insulin resistance, androgen excess, and metabolic dysfunction has the same underlying condition and the same treatment priorities. A 2022 systematic review ¹ confirms that PCOS involves complex metabolic disturbances alongside reproductive symptoms, whilst a 2014 analysis ⁷ explicitly identifies metabolic disturbances as central to the condition's pathology. The name PMOS reflects this metabolic reality.

The metabolic mechanism: insulin resistance at the centre

Here is what is actually happening in PMOS: your cells struggle to respond properly to insulin. When you eat, your pancreas releases insulin to move glucose into cells. In PMOS, that signal is weakened — cells don't listen as well. Your pancreas responds by producing more insulin, flooding your bloodstream. This excess insulin signals your ovaries to produce more androgens (testosterone, androstenedione). Elevated androgens disrupt the follicles in your ovaries, preventing normal egg release and creating irregular cycles. They also trigger acne, unwanted hair growth, and hair loss.

This is not a reproductive disease with metabolic side effects. It is a metabolic disease with reproductive consequences. This distinction is crucial because it means your food choices are not optional decoration — they are medical intervention. Controlling blood glucose and insulin response is not lifestyle optimisation; it is disease management.

PMOS is not one condition: understanding subtypes

A 2020 genetic study ⁴ performed an unsupervised clustering analysis of 6,874 women with PCOS and identified distinct subtypes with novel genetic associations. The research revealed that PMOS phenotypes do not sit on a single spectrum; they cluster into separate groups with different genetic architectures. This means your neighbour with PCOS might have a completely different genetic risk profile and metabolic pattern than you, which explains why one woman thrives on a certain macronutrient ratio whilst another does not.

Some women present with clear insulin resistance and metabolic dysfunction (the metabolic-ovulatory type). Others have milder metabolic involvement but severe androgen excess (the mild-metabolic type). Still others have normal metabolic markers but classical PCOS features. Knowing which subtype you occupy — or which metabolic markers are driving your symptoms — lets you tailor intervention rather than applying a generic PCOS diet.

Diagnosis requires metabolic testing

If PMOS is metabolic first, then diagnosis should include metabolic testing first. The standard workup should include:

• Fasting insulin and glucose
• Homeostasis model assessment of insulin resistance (HOMA-IR)
• Two-hour glucose tolerance test or HbA1c
• Lipid profile (triglycerides and HDL are especially sensitive to insulin resistance)
• Free and total testosterone, DHEA-S, androstenedione
• Transvaginal ultrasound (if available, to assess ovarian morphology)

Many GPs order testosterone and an ultrasound, then stop. That is incomplete. You need the insulin picture. Without it, you cannot know whether you are simply irregular because of extreme metabolic dysfunction, or whether your metabolic markers are within textbook range and something else is driving your symptoms. A 2010 analysis ³ confirms that PCOS involves metabolic manifestations across the lifespan — some women show metabolic derangement in adolescence, others much later. Testing tells you where you stand.

What this means for treatment

Because PMOS is metabolic-first, first-line treatment is dietary and lifestyle: specifically, eating in a way that minimises blood glucose spikes and supports insulin sensitivity. This is not calorie restriction or low fat. It is prioritising protein and fibre, spacing carbohydrates appropriately, and choosing carbohydrates that do not flood your bloodstream.

Medication (metformin, GLP-1 agonists, anti-androgen therapy) addresses the downstream consequences. Food addresses the root. This is why women with PMOS often see the most dramatic improvements when they combine metabolic awareness with medical intervention, rather than pursuing either alone.

Your next step: get metabolic clarity

• Request fasting insulin and HOMA-IR at your next blood test; if your GP hesitates, ask why and consider seeing an endocrinologist.
• Document your own symptoms: when do you see energy crashes, mood dips, or hunger spikes? These often correlate with insulin dysregulation.
• Review your lipid profile; elevated triglycerides or low HDL are red flags for insulin resistance even if your glucose is normal.
• Begin tracking meals that stabilise vs. destabilise your energy and appetite — this is free data about your personal metabolic response.
• If you have a genetic or family history of type 2 diabetes, bring this to your clinician; PMOS carries metabolic risk across generations.